My major research interest is in radiation therapy for lymphomas, genitourinary cancers—including prostate cancer, bladder cancer and seminoma—and late effects of treatment, especially second cancers. Current research activities include study of image guided precision radiotherapy. I also have a long-standing interest in cancer classification with an emphasis on staging and prognostic factors. In addition, my current interests include the application of modern information and communication technologies in cancer control.
Mary K Gospodarowicz
Jpn J Clin Oncol. 2017 Oct 25;:1-4
Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction.
Int J Radiat Oncol Biol Phys. 2017 Aug 01;98(5):1116-1123
The TNM classification of malignant tumours-towards common understanding and reasonable expectations.
Lancet Oncol. 2017 Jul;18(7):849-851
Am Soc Clin Oncol Educ Book. 2017;37:395-402
Improved outcomes with dose escalation in localized prostate cancer treated with precision image-guided radiotherapy.
Radiother Oncol. 2017 Apr 20;:
Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.
J Clin Oncol. 2011 May 20;29(15_suppl):8035
A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013).
J Clin Oncol. 2011 May 20;29(15_suppl):4514
J Clin Oncol. 2011 May 20;29(15_suppl):4565
Development of clinical research process metrics and tracking improvement in quality assurance in clinical trials.
J Clin Oncol. 2011 May 20;29(15_suppl):e16572
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Professor, Department of Radiation Oncology, University of Toronto
President, Union for International Cancer Control (UICC)